Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peptide Vaccination and IL-2 in Recurrent Pediatric Sarcomas
NCT00001564Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 1996
- Primary completion
- Oct 2007
- Modality
- Peptides, Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of EF-1 Peptide Vaccine, EF-2 Peptide Vaccine, tumor antigen-pulsed dendritic cell vaccine (NCI) and HPV16 E7 peptide vaccine in Ewing sarcoma and alveolar rhabdomyosarcoma (ARMS) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Safety and Toxicity. Started Dec 1996; status: completed.
02
Drugs
EF-1 Peptide VaccineEF-2 Peptide Vaccinetumor antigen-pulsed dendritic cell vaccine (NCI)HPV16 E7 peptide vaccine
03
Conditions
Ewing sarcomaalveolar rhabdomyosarcoma (ARMS)
Beyond the preview
Go deeper on NCT00001564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001564.